Exploring Antibody Therapy in ALL: How and Why to Integrate Antibody-Based Treatment Into Patient Management

Webcast (ASH-registration required)

Chair & Presenter: Professor David I. Marks, MB, MS, FRACP, PhD, FRCPath: University Hospitals Bristol NHS Foundation Trust - Bristol, United Kingdom

• TKI-based in-duction chemotherapy, followed by allogeneic hematopoietic cell transplantation (HCT) during the first complete remission (CR), is the standard of care for ALL patients. 

Presenter: Daniel J. DeAngelo, MD, PhD: Dana-Farber Cancer Institute - Harvard Medical School - Boston, Massachusetts¨

• With the development of antibody-based therapies such as monoclonal antibodies, ADCs, bispecific, tri-specific, and even multi-specific antibodies, treatment options are widely expanded.

Presenter: Nicholas J. Short, MD: The University of Texas - MD Anderson Cancer Center Houston, Texas

• Emerging data indicate that combinations with blinatumomab, including with cytotoxic chemotherapy and/or INO, are highly effective for the frontline treatment of B-cell ALL in both older and younger adults, as well as for those with relapsed/refractory disease.